IMR OpenIR
Investigation of the Sequential Actions of Doxorubicin and p53 on Tumor Cell Growth Via Branched Polyethylenimine-beta-cyclodextrin Conjugates
Xie, B; Peng, J; Wang, S; Zhang, X; Nie, HM; Nie, HM (reprint author), Hunan Univ, Dept Biomed Engn, Changsha 410082, Hunan, Peoples R China.
2016-11-01
Source PublicationANNALS OF BIOMEDICAL ENGINEERING
ISSN0090-6964
Volume44Issue:11Pages:3372-3383
AbstractThe combination of gene therapy and chemotherapy has showed increased therapeutic efficacy in the treatment of cancers, but it is not well investigated about the actual coordination pattern between therapeutic gene and chemical drug. In this work, p53/BPEI-beta-CD/AD-dox complex was fabricated and employed to investigate the interaction manner between p53 and doxorubicin (Dox). Briefly, branched polyethylenimine (BPEI) was conjugated with beta-cyclodextrin hydrate (beta-CD) to form BPEI-beta-CD backbone, and p53 plasmid was condensed by positively charged BPEI via electrostatic interaction, while Dox was first conjugated with adamantine (AD) and then assembled with BPEI-beta-CD backbone via the host-guest interaction. It was found that the BPEI-beta-CD backbone possessed high endocytosis efficiency but low cytotoxicity. Moreover, p53/BPEI-beta-CD/AD-dox complex released Dox and enabled the expression of p53 gene in a sequential manner, and the released Dox and expressed p53 gene showed successive inhibition of the growth of HeLa cells in vitro. With the ability to co-deliver chemical drug and therapeutic gene and exert their inhibitory actions on tumor cell growth in a sequential manner, this DNA/BPEI-beta-CD/AD-drug complex via electrostatic interaction and host-guest assembly not only achieved long-term efficacy in inhibiting tumor cell growth but also can be employed as a platform to investigate the coordination pattern between chemical drugs and therapeutic genes for other purposes.
description.department[xie, bei ; peng, jian ; wang, shuo ; nie, hemin] hunan univ, dept biomed engn, changsha 410082, hunan, peoples r china ; [zhang, xing] chinese acad sci, shenyang natl lab mat sci, inst met res, 72 wenhua rd, shenyang 110016, liaoning, peoples r china
KeywordBpei-beta-cd Doxorubicin P53 Co-delivery Sequential Actions
Subject AreaEngineering, Biomedical
Funding OrganizationNational Natural Science Foundation of China [31200727, 31300788]; Natural Science Foundation of Hunan Province [2015JJ1007]; Hunan University Fund for Interdisciplinary Research [2015JCA02]
Indexed Bysci
Language英语
Document Type期刊论文
Identifierhttp://ir.imr.ac.cn/handle/321006/76194
Collection中国科学院金属研究所
Corresponding AuthorNie, HM (reprint author), Hunan Univ, Dept Biomed Engn, Changsha 410082, Hunan, Peoples R China.
Recommended Citation
GB/T 7714
Xie, B,Peng, J,Wang, S,et al. Investigation of the Sequential Actions of Doxorubicin and p53 on Tumor Cell Growth Via Branched Polyethylenimine-beta-cyclodextrin Conjugates[J]. ANNALS OF BIOMEDICAL ENGINEERING,2016,44(11):3372-3383.
APA Xie, B,Peng, J,Wang, S,Zhang, X,Nie, HM,&Nie, HM .(2016).Investigation of the Sequential Actions of Doxorubicin and p53 on Tumor Cell Growth Via Branched Polyethylenimine-beta-cyclodextrin Conjugates.ANNALS OF BIOMEDICAL ENGINEERING,44(11),3372-3383.
MLA Xie, B,et al."Investigation of the Sequential Actions of Doxorubicin and p53 on Tumor Cell Growth Via Branched Polyethylenimine-beta-cyclodextrin Conjugates".ANNALS OF BIOMEDICAL ENGINEERING 44.11(2016):3372-3383.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Xie, B]'s Articles
[Peng, J]'s Articles
[Wang, S]'s Articles
Baidu academic
Similar articles in Baidu academic
[Xie, B]'s Articles
[Peng, J]'s Articles
[Wang, S]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Xie, B]'s Articles
[Peng, J]'s Articles
[Wang, S]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.